Background Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy
of childhood. Untreated, this incurable disease, which has an X‐linked recessive …

Duchenne muscular dystrophy (DMD) is a severe, progressive disease that affects 1 in 3600–
6000 live male births. Although guidelines are available for various aspects of DMD …

Optimum management of Duchenne muscular dystrophy (DMD) requires a multidisciplinary
approach that focuses on anticipatory and preventive measures as well as active …

Background Pharmacological corticosteroid therapy is the standard of care in Duchenne
Muscular Dystrophy (DMD) that aims to control symptoms and slow disease progression …

Objective: To document the effects of long-term daily corticosteroid treatment on a variety of
orthopedic outcomes in boys with Duchenne muscular dystrophy. Methods: We reviewed the …

Over the years various steroid trials have been conducted in Duchenne muscular dystrophy
(DMD). In children who are still able to walk as well as in those who are wheelchair‐bound …

Dual-energy X-ray absorptiometry (DXA) is the most widely used technical instrument for
evaluating bone mineral content (BMC) and density (BMD) in patients of all ages. However …

Patients affected by Duchenne muscular dystrophy (DMD) and dystrophic MDX mice were
investigated in this study for their bone phenotype and systemic regulators of bone turnover …

Thirty-two participants representing parents, funding agencies and clinicians involved in the
care of children with Duchenne Muscular Dystrophy (DMD) from Belgium, Canada …

Steadily improving management of Duchenne muscular dystrophy (DMD) continues to lead
to improved physical and functional status, allowing increasingly successful transitions to …